Haisco Pharmaceutical Group's (SHE:002653) subsidiary, Shanghai Hisun Pharmaceutical Technology, received approval from China's National Medical Products Administration to conduct clinical trials on four drugs, according to a Wednesday filing on the Shenzhen bourse.

The drugs are the HSK45019 tablets, HSK50042 tablets, HSK55718 injection and HSK36357 capsules, which will be tested as a treatment for inflammatory bowel disease, respiratory diseases, acute pain and muscular dystrophy, respectively.